Barclays takes a dimmer view of shares of Pfizer (PFE), downgrading the drugmaker to Equal...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

Barclays takes a dimmer view of shares of Pfizer (PFE), downgrading the drugmaker to Equal Weight and cutting its price target by $2 to $19. Analysts see limited upside potential in the near-term, and say patent expiration will kick in and pressure the firm in the long-term. Shares -0.5% premarket.